Header Logo

DANIEL HAMSTRA

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Radiation Oncology
Address7200 CAMBRIDGE
vCardDownload vCard
    Other Positions
    TitleChair
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Radiation Oncology
    DivisionRadiation Oncology


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Patel SA, Patil D, Smith J, Saigal CS, Litwin MS, Hu JC, Cooperberg MR, Carroll PR, Klein EA, Kibel AS, Andriole GL, Han M, Michalski JM, Wood DP, Hembroff LA, Spratt DE, Wei JT, Sandler HM, Hamstra DA, Pisters L, Kuban D, Regan MM, Wagner A, Crociani CM, Kaplan I, Sanda MG, Chang P, PROST-QA/RP2 Consortium. Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life. JAMA Netw Open. 2024 Oct 01; 7(10):e2440747. PMID: 39446326; PMCID: PMC11581678.
      Citations:    Fields:    Translation:Humans
    2. Dong EE, Xu J, Kim JW, Bryan J, Appleton J, Hamstra DA, Ludwig MS, Hanania AN. Apparent diffusion coefficient values predict response to brachytherapy in bulky cervical cancer. Radiat Oncol. 2024 Mar 13; 19(1):35. PMID: 38481285; PMCID: PMC10936078.
      Citations:    Fields:    Translation:Humans
    3. Seymour ZA, Pinkawa M, Daignault-Newton S, Bosch W, Michalski JM, Gay H, Hamstra DA. A pooled long-term follow-up after radiotherapy for prostate cancer with and without a rectal hydrogel spacer: impact of hydrogel on decline in sexual quality of life. Front Oncol. 2023; 13:1239104. PMID: 37886176; PMCID: PMC10599244.
      Citations: 1     
    4. Baliga S, Patel S, Naqa IE, Li XA, Cohen LE, Howell RM, Hoppe BS, Constine LS, Palmer JD, Hamstra D, Olch AJ. Testicular Dysfunction in Male Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. Int J Radiat Oncol Biol Phys. 2024 Jun 01; 119(2):610-624. PMID: 37791936.
      Citations:    Fields:    
    5. Jansen M, Van der Does AJW, De Rover M, De Bruijn ERA, Hamstra DA. Hormonal status effects on the electrophysiological correlates of performance monitoring in women. Psychoneuroendocrinology. 2023 03; 149:106006. PMID: 36566721.
      Citations:    
    6. Quinn TJ, Chapman D, Parzen J, Wahl DR, McNamara A, Dess R, Chan J, Feng F, Jackson WC, Hamstra D. Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation Therapy. Pract Radiat Oncol. 2023 Mar-Apr; 13(2):e166-e175. PMID: 36503624.
      Citations:    Fields:    Translation:Humans
    7. Sapienza LG, Thomas JJ, Echeverria AE, Sharma S, Hamstra DA, Hall TR, Ludwig MS. Predictors of follow-up non-compliance after definitive radiotherapy for locally advanced cervical cancer at a community cancer center. Gynecol Oncol Rep. 2022 Dec; 44:101091. PMID: 36325116; PMCID: PMC9618769.
      Citations:    
    8. Jafferji M, Hamstra DA, Groth SS. Stereotactic Body Radiation Therapy vs Surgery for Early-Stage Non-Small Cell Lung Cancer: Does the Dealer Influence the Choice? Ann Thorac Surg. 2023 02; 115(2):354-355. PMID: 36070808.
      Citations:    
    9. Delaney RK, Sisco-Taylor BL, Wang X, Scherr K, Ubel PA, Haaland B, Kahn VC, Hamstra D, Wei JT, Madanay F, Davis JK, Greeno TU, Fagerlin A. Two Specialists, Two Recommendations: Discordance Between Urologists' & Radiation Oncologists' Prostate Cancer Treatment Recommendations. Urology. 2022 11; 169:156-161. PMID: 35768027; PMCID: PMC10049001.
      Citations:    Fields:    
    10. Seymour ZA, Daignault-Newton S, McLaughlin PW, Sandler H, Jackson W, Johnson SB, Miller D, Wei J, Sanda M, Hamstra DA. Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment. Clin Transl Radiat Oncol. 2022 Sep; 36:56-62. PMID: 35813938; PMCID: PMC9256969.
      Citations:    
    11. Rao A, Moka N, Hamstra DA, Ryan CJ. Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now? Cancers (Basel). 2022 Feb 04; 14(3). PMID: 35159068; PMCID: PMC8834038.
      Citations: 2     
    12. Campbell KC, Rehemtulla A, Sunkara P, Hamstra D, Buhnerkempe M, Ross B. Oral D-methionine protects against cisplatin-induced hearing loss in humans: phase 2 randomized clinical trial in India. Int J Audiol. 2022 08; 61(8):621-631. PMID: 34622731.
      Citations: 1     Fields:    
    13. Scherr K, Delaney RK, Ubel P, Kahn VC, Hamstra D, Wei JT, Fagerlin A. Preparing Patients with Early Stage Prostate Cancer to Participate in Clinical Appointments Using a Shared Decision Making Training Video. Med Decis Making. 2022 04; 42(3):364-374. PMID: 34617827; PMCID: PMC8918874.
      Citations:    Fields:    Translation:Humans
    14. Parzen JS, Hamstra DA. Patient-Reported Quality of Life During Prostate Cancer Radiation Therapy: Insights Into the Patient Experience. Int J Radiat Oncol Biol Phys. 2021 07 15; 110(4):1129-1131. PMID: 34171237.
      Citations:    Fields:    Translation:Humans
    15. Grzywacz V, Quinn TJ, Wilson T, Reitemeier P, Navin M, Hamstra D, Anderson J, Chinnaiyan P, Stevens C, Kabolizadeh P. Ethical Allocation of Proton Therapy and the Insurance Review Process. Pract Radiat Oncol. 2021 Sep-Oct; 11(5):e449-e458. PMID: 33548544.
      Citations:    Fields:    Translation:Humans
    16. Thompson AB, Hamstra DA. Rectal Spacer Usage with Proton Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):644-648. PMID: 32976788.
      Citations:    Fields:    Translation:Humans
    17. Seymour ZA, Hamstra DA, Daignault-Newton S, Bosch W, Michalski J, Gay HA, Pinkawa M. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life. BJU Int. 2020 09; 126(3):367-372. PMID: 32333714.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    18. Levitin RB, Hamstra DA. Local control matters. Transl Androl Urol. 2020 Jun; 9(3):991-996. PMID: 32676381; PMCID: PMC7354304.
      Citations: 1     
    19. Hagan M, Kapoor R, Michalski J, Sandler H, Movsas B, Chetty I, Lally B, Rengan R, Robinson C, Rimner A, Simone C, Timmerman R, Zelefsky M, DeMarco J, Hamstra D, Lawton C, Potters L, Valicenti R, Mutic S, Bosch W, Abraham C, Caruthers D, Brame R, Palta JR, Sleeman W, Nalluri J. VA-Radiation Oncology Quality Surveillance Program. Int J Radiat Oncol Biol Phys. 2020 03 01; 106(3):639-647. PMID: 31983560.
      Citations: 4     Fields:    Translation:Humans
    20. Quinn TJ, Daignault-Newton S, Bosch W, Mariados N, Sylvester J, Shah D, Gross E, Hudes R, Beyer D, Kurtzman S, Bogart J, Hsi RA, Kos M, Ellis R, Logsdon M, Zimberg S, Forsythe K, Zhang H, Soffen E, Francke P, Mantz C, DeWeese T, Gay HA, Michalski J, Hamstra DA. Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. Pract Radiat Oncol. 2020 May - Jun; 10(3):186-194. PMID: 31978591.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    21. Quinn TJ, Hamstra D. Hypofractionation in Prostate Cancer Using Proton Beam. Int J Radiat Oncol Biol Phys. 2019 11 15; 105(4):723-726. PMID: 31655657.
      Citations: 1     Fields:    Translation:Humans
    22. Hamstra DA, Pugh SL, Lepor H, Rosenthal SA, Pienta KJ, Gomella L, Peters C, D'Souza DP, Zeitzer KL, Jones CU, Hall WA, Horwitz E, Pisansky TM, Souhami L, Hartford AC, Dominello M, Feng F, Sandler HM. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiother Oncol. 2019 12; 141:137-143. PMID: 31540746; PMCID: PMC6912855.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    23. Quinn TJ, Almahariq MF, Siddiqui ZA, Thompson AB, Hamstra DA, Kabolizadeh P, Gowans KL, Chen PY. Trimodality therapy for atypical teratoid/rhabdoid tumor is associated with improved overall survival: A surveillance, epidemiology, and end results analysis. Pediatr Blood Cancer. 2019 12; 66(12):e27969. PMID: 31464041.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    24. Foster B, Jackson W, Foster C, Dess R, Abu-Isa E, McLaughlin PW, Merrick G, Hearn J, Spratt D, Liauw S, Hamstra D. Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization. Am J Clin Oncol. 2019 04; 42(4):382-390. PMID: 30724780.
      Citations:    Fields:    Translation:Humans
    25. Dignam JJ, Hamstra DA, Lepor H, Grignon D, Brereton H, Currey A, Rosenthal S, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Sandler HM. Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol. 2019 01 20; 37(3):213-221. PMID: 30526194; PMCID: PMC6338393.
      Citations: 6     Fields:    Translation:Humans
    26. Seymour Z, Hamstra D. Quality of life is not compromised with intensification of androgen therapy in recurrent prostate cancer. Lancet Oncol. 2018 10; 19(10):1275-1276. PMID: 30213450.
      Citations: 1     Fields:    Translation:Humans
    27. Johnson SB, Hung J, Kapadia N, Oh KS, Kim M, Hamstra DA. Spinal Growth Patterns After Craniospinal Irradiation in Children With Medulloblastoma. Pract Radiat Oncol. 2019 Jan; 9(1):e22-e28. PMID: 30036592.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    28. Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Lau H, Duclos M, Parliament M, Morton G, Hamstra D, Seider M, Lock MI, Patel M, Gay H, Vigneault E, Winter K, Sandler H, Bahary JP. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018 06 14; 4(6):e180039. PMID: 29543933; PMCID: PMC5885160.
      Citations: 82     Fields:    Translation:HumansPHPublic Health
    29. Hamstra DA. In Regard to Jang et?al. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1292-1293. PMID: 29722666.
      Citations:    Fields:    
    30. Litzenberg DW, Muenz DG, Archer PG, Jackson WC, Hamstra DA, Hearn JW, Schipper MJ, Spratt DE. Changes in prostate orientation due to removal of a Foley catheter. Med Phys. 2018 Apr; 45(4):1369-1378. PMID: 29474748.
      Citations: 2     Fields:    Translation:Humans
    31. Hamstra DA, Lee KC, Eisbruch A, Sunkara P, Borgonha S, Phillip B, Campbell KCM, Ross BD, Rehemtulla A. Double-blind placebo-controlled multicenter phase II trial to evaluate D-methionine in preventing/reducing oral mucositis induced by radiation and chemotherapy for head and neck cancer. Head Neck. 2018 07; 40(7):1375-1388. PMID: 29473247.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    32. Dess RT, Devasia TP, Aghdam N, Jackson WC, Soni PD, Smith CP, Mitchell AL, Suy S, Hamstra DA, Jolly S, Nguyen PL, Feng FY, Schipper MJ, Skolarus TA, Miller DC, Wittmann DA, Collins SP, Spratt DE. Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):376-386. PMID: 29487023.
      Citations:    Fields:    Translation:Humans
    33. Hamstra DA, Feng FY, Spratt DE, Moraes FY, Leite ETT, Arruda FF, Gadia R, Abreu CECV, Marta GN, Hanna SA, Silva JLFD, Carvalho HA. Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving Radiotherapy. Am J Clin Oncol. 2018 Jan; 41(1):6-12. PMID: 26703812.
      Citations: 4     Fields:    Translation:Humans
    34. Karsh LI, Gross ET, Pieczonka CM, Aliotta PJ, Skomra CJ, Ponsky LE, Nieh PT, Han M, Hamstra DA, Shore ND. Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. Urology. 2018 May; 115:39-44. PMID: 29174940.
      Citations: 29     Fields:    Translation:Humans
    35. Masi K, Archer P, Jackson W, Sun Y, Schipper M, Hamstra D, Matuszak M. Knowledge-based treatment planning and its potential role in the transition between treatment planning systems. Med Dosim. 2018 Autumn; 43(3):251-257. PMID: 29174796.
      Citations: 4     Fields:    Translation:Humans
    36. Yu JB, Hamstra D. Point: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Quality of Life is Better After Modern Radiotherapy Compared With Surgery. Oncology (Williston Park). 2017 11 15; 31(11):830-2, 835. PMID: 29179251.
      Citations:    Fields:    Translation:Humans
    37. Hamstra DA, de Kloet ER, de Rover M, Van der Does W. Oral contraceptives positively affect mood in healthy PMS-free women: A longitudinal study. J Psychosom Res. 2017 12; 103:119-126. PMID: 29167038.
      Citations: 4     Fields:    Translation:Humans
    38. Dess RT, Hartman HE, Aghdam N, Jackson WC, Soni PD, Abugharib AE, Suy S, Desai NB, Zumsteg ZS, Mehra R, Morgan TM, Feng FY, Hamstra DA, Schipper MJ, Collins SP, Spratt DE. Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU Int. 2018 01; 121(1):61-68. PMID: 28710895.
      Citations: 6     Fields:    Translation:Humans
    39. Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):40-47. PMID: 29304991.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    40. Hamstra DA. Don't Bet Against the Elderly. Int J Radiat Oncol Biol Phys. 2017 09 01; 99(1):7. PMID: 28816163.
      Citations:    Fields:    Translation:Humans
    41. Hamstra DA, Feng FY, Liauw SL, Son CH. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir =0.2 to Select Men for Short-term Hormonal Therapy. Am J Clin Oncol. 2017 Aug; 40(4):348-352. PMID: 25436827.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    42. Hamstra DA, Mariados N, Sylvester J, Shah D, Gross E, Hudes R, Beyer D, Kurtzman S, Bogart J, Hsi RA, Kos M, Ellis R, Logsdon M, Zimberg S, Forsythe K, Zhang H, Soffen E, Francke P, Mantz C, Rossi P, DeWeese T, Daignault-Newton S, Fischer-Valuck BW, Chundury A, Gay HA, Bosch W, Michalski J. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):e7-e15. PMID: 28951089.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    43. Hamstra DA, Krauss D, Buyyounouski MK. In Regard to Morris et?al. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):481-482. PMID: 28463168.
      Citations:    Fields:    
    44. Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 2017 09; 120(3):351-357. PMID: 28139024.
      Citations: 3     Fields:    Translation:Humans
    45. Gay HA, Sanda MG, Liu J, Wu N, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal CS, Litwin MS, Kuban DA, Hembroff L, Regan MM, Chang P, Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium, Michalski JM. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):304-317. PMID: 28463150; PMCID: PMC5493021.
      Citations: 9     Fields:    Translation:Humans
    46. Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, Kurtzman S, Bogart J, Hsi RA, Kos M, Ellis R, Logsdon M, Zimberg S, Forsythe K, Zhang H, Soffen E, Francke P, Mantz C, Rossi P, DeWeese T, Daignault-Newton S, Fischer-Valuck BW, Chundury A, Gay H, Bosch W, Michalski J. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of?a?Phase III Trial. Int J Radiat Oncol Biol Phys. 2017 04 01; 97(5):976-985. PMID: 28209443.
      Citations: 106     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    47. Dess RT, Jackson WC, Suy S, Soni PD, Lee JY, Abugharib AE, Zumsteg ZS, Feng FY, Hamstra DA, Collins SP, Spratt DE. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer. 2017 05 01; 123(9):1635-1642. PMID: 28001303.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    48. Hamstra DA, de Kloet ER, Quataert I, Jansen M, Van der Does W. Mineralocorticoid receptor haplotype, estradiol, progesterone and emotional information processing. Psychoneuroendocrinology. 2017 02; 76:162-173. PMID: 27936434.
      Citations: 10     Fields:    Translation:Humans
    49. Upadhyaya SA, Koschmann C, Muraszko K, Venneti S, Garton HJ, Hamstra DA, Maher CO, Betz BL, Brown NA, Wahl D, Weigelin HC, DuRoss KE, Leonard AS, Robertson PL. Brainstem Low-Grade Gliomas in Children-Excellent Outcomes With Multimodality Therapy. J Child Neurol. 2017 02; 32(2):194-203. PMID: 27810966; PMCID: PMC5582383.
      Citations: 6     Fields:    Translation:Humans
    50. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Oct 20; 34(30):3648-3654. PMID: 27528718.
      Citations: 93     Fields:    
    51. Caffo O, Thompson C, De Santis M, Kragelj B, Hamstra DA, Fellin G, Pappagallo GL, Galligioni E, Choudhury A, Azria D. Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials. Radiother Oncol. 2016 11; 121(2):193-198. PMID: 27720221.
      Citations: 8     Fields:    Translation:Humans
    52. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1046-1053. PMID: 27745980.
      Citations: 13     Fields:    Translation:Humans
    53. Chang P, Regan MM, Patil D, Wei JT, Hembroff LA, Michalski JM, Saigal CS, Litwin MS, Hamstra DA, Kaplan ID, Ciezki JP, Klein EA, Kibel AS, Sandler HM, Dunn RL, Crociani CM, Sanda MG, PROST-QA Consortium, Ferrer M, Guedea F. Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. J Urol. 2017 02; 197(2):376-384. PMID: 27593476; PMCID: PMC5501938.
      Citations: 6     Fields:    Translation:Humans
    54. Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Hamstra DA, Spratt DE, Garin O, Ferrer M. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):770-777. PMID: 27663760.
      Citations: 2     Fields:    Translation:Humans
    55. Mak RH, Hunt D, Efstathiou JA, Heney NM, Jones CU, Lukka HR, Patel M, Balogh A, Leibenhaut MH, Hamstra DA, Roof KS, Jeffrey Lee R, Gore EM, Sandler HM, Shipley WU, Bahary JP, Nabid A. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urol Oncol. 2016 10; 34(10):430.e1-7. PMID: 27381895; PMCID: PMC5035191.
      Citations: 6     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    56. Hamstra DA, de Kloet ER, Tollenaar M, Verkuil B, Manai M, Putman P, Van der Does W. Mineralocorticoid receptor haplotype moderates the effects of oral contraceptives and menstrual cycle on emotional information processing. J Psychopharmacol. 2016 10; 30(10):1054-61. PMID: 27222270.
      Citations: 7     Fields:    Translation:Humans
    57. Spratt DE, Jackson WC, Abugharib A, Tomlins SA, Dess RT, Soni PD, Lee JY, Zhao SG, Cole AI, Zumsteg ZS, Sandler H, Hamstra D, Hearn JW, Palapattu G, Mehra R, Morgan TM, Feng FY. Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. Prostate Cancer Prostatic Dis. 2016 09; 19(3):292-7. PMID: 27215611.
      Citations:    
    58. Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Neoplasia. 2016 04; 18(4):213-22. PMID: 27108384; PMCID: PMC4840291.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    59. McLaughlin PW, Merrick GS, Vainshtein JM, Hamstra DA, Shilkrut M. Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy. Am J Clin Oncol. 2016 Apr; 39(2):181-8. PMID: 24517957.
      Citations: 2     Fields:    Translation:Humans
    60. Schipper M, Vance S, Feng FY, Olson KB, Hamstra DA, Vainshtein JM. Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy. Am J Clin Oncol. 2016 Apr; 39(2):173-80. PMID: 24487421.
      Citations: 2     Fields:    Translation:Humans
    61. Jackson WC, Feng FY, Daignault S, Hussain M, Smith D, Cooney K, Pienta K, Jolly S, Hollenbeck B, Olson KB, Sandler HM, Ray ME, Hamstra DA. A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. Adv Radiat Oncol. 2016 Jan-Mar; 1(1):59-66. PMID: 28799570; PMCID: PMC5506748.
      Citations: 4     
    62. Bernat JK, Wittman DA, Hawley ST, Hamstra DA, Helfand AM, Haggstrom DA, Darwish-Yassine M, Skolarus TA. Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care. BJU Int. 2016 09; 118(3):372-8. PMID: 26389529; PMCID: PMC4835263.
      Citations: 20     Fields:    Translation:Humans
    63. Magers MJ, Zhan T, Udager AM, Wei JT, Tomlins SA, Wu AJ, Kunju LP, Lew M, Feng FY, Hamstra DA, Siddiqui J, Chinnaiyan AM, Montgomery JS, Weizer AZ, Morgan TM, Hollenbeck BK, Miller DC, Palapattu GS, Jiang H, Mehra R. Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. Med Oncol. 2015 Nov; 32(11):249. PMID: 26442515.
      Citations:    Fields:    Translation:Humans
    64. Johnson SB, Jackson WC, Murgic J, Feng FY, Hamstra DA. Time to Nadir PSA: Of Popes and PSA--The Immortality Bias. Am J Clin Oncol. 2015 Oct; 38(5):465-71. PMID: 24064749.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    65. Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA, PROSTQA Study Consortium. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015 Aug; 116(2):179-84. PMID: 26276528.
      Citations: 19     Fields:    Translation:Humans
    66. Mariados N, Hamstra DA. In Reply to King et al. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):937-9. PMID: 26530768.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    67. Jackson WC, Johnson SB, Feng FY, Hamstra DA. Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol. 2015 Aug; 38(4):367-72. PMID: 23822986.
      Citations: 2     Fields:    Translation:Humans
    68. Shumway DA, Hamstra DA. Reply to G. Gandaglia et al and K. Lu. J Clin Oncol. 2015 Sep 01; 33(25):2833-4. PMID: 26215955.
      Citations:    Fields:    Translation:Humans
    69. Rosenthal SA, Hunt D, Sartor AO, Pienta KJ, Gomella L, Grignon D, Rajan R, Kerlin KJ, Jones CU, Dobelbower M, Shipley WU, Zeitzer K, Hamstra DA, Donavanik V, Rotman M, Hartford AC, Michalski J, Seider M, Kim H, Kuban DA, Moughan J, Sandler H. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys. 2015 Oct 01; 93(2):294-302. PMID: 26209502; PMCID: PMC4719152.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    70. Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol. 2016 Jan; 69(1):50-7. PMID: 26004800.
      Citations: 9     Fields:    Translation:Humans
    71. Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, Davicioni E, Feng FY. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):229-36. PMID: 25986914; PMCID: PMC4579590.
      Citations:    
    72. Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, Kurtzman S, Bogart J, Hsi RA, Kos M, Ellis R, Logsdon M, Zimberg S, Forsythe K, Zhang H, Soffen E, Francke P, Mantz C, Rossi P, DeWeese T, Hamstra DA, Bosch W, Gay H, Michalski J. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric?and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate?Image Guided Intensity Modulated Radiation?Therapy. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):971-977. PMID: 26054865.
      Citations: 106     Fields:    Translation:HumansPHPublic Health
    73. Liss AL, Abu-Isa EI, Jawad MS, Feng FY, Vance SM, Winfield RJ, Narayana V, Sandler HM, McLaughlin PW, Hamstra DA. Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5. Brachytherapy. 2015 Jul-Aug; 14(4):502-10. PMID: 25911994.
      Citations: 4     Fields:    Translation:Humans
    74. Koloff ZB, Hamstra DA, Wei JT, Montgomery JS, Tomlins SA, Wu AJ, Morgan TM, Siddiqui J, Paich K, Chinnaiyan AM, Feng FY, Weizer AZ, Kunju LP, Hollenbeck BK, Miller DC, Palapattu GS, Mehra R. Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. Asian J Urol. 2015 Jan; 2(1):53-58. PMID: 29264120; PMCID: PMC5730694.
      Citations: 3     
    75. Walston S, Hamstra DA, Oh K, Woods G, Guiou M, Olshefski RS, Chakravarti A, Williams TM. A multi-institutional experience in pediatric high-grade glioma. Front Oncol. 2015; 5:28. PMID: 25741472; PMCID: PMC4332307.
      Citations: 8     
    76. Shumway DA, Hamstra DA. Ageism in the undertreatment of high-risk prostate cancer: how long will clinical practice patterns resist the weight of evidence? J Clin Oncol. 2015 Mar 01; 33(7):676-8. PMID: 25559801.
      Citations: 3     Fields:    Translation:Humans
    77. Hamstra DA, de Kloet ER, van Hemert AM, de Rijk RH, Van der Does AJ. Mineralocorticoid receptor haplotype, oral contraceptives and emotional information processing. Neuroscience. 2015 Feb 12; 286:412-22. PMID: 25497375.
      Citations:    
    78. Foster CC, Jackson WC, Foster BC, Johnson SB, Feng FY, Hamstra DA. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. Radiat Oncol. 2014 Nov 26; 9:245. PMID: 25424123; PMCID: PMC4255426.
      Citations:    Fields:    Translation:Humans
    79. Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M, Lawton CA, Sandler HM. Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar 15; 121(6):844-52. PMID: 25410885; PMCID: PMC4657945.
      Citations: 1     Fields:    Translation:Humans
    80. Hamstra DA. From the guest editor: Proton therapy: current evidence, challenges, and future plans. Cancer J. 2014 Nov-Dec; 20(6):369-70. PMID: 25415680.
      Citations: 1     Fields:    Translation:Humans
    81. Hamstra DA, Johnson SB, Daignault S, Zikmund-Fisher BJ, Taylor JM, Larkin K, Wood A, Fagerlin A. The impact of numeracy on verbatim knowledge of the longitudinal risk for prostate cancer recurrence following radiation therapy. Med Decis Making. 2015 01; 35(1):27-36. PMID: 25277673; PMCID: PMC4567273.
      Citations: 10     Fields:    Translation:Humans
    82. Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, Blute M, Catto J, Chen RC, D'Amico AV, Fitzpatrick JM, Frank SJ, Frydenberg M, Glaser A, Graefen M, Hamstra D, Kibel A, Mendenhall N, Moretti K, Ramon J, Roos I, Sandler H, Sullivan FJ, Swanson D, Tewari A, Vickers A, Wiegel T, Huland H, Feick G, Froehner M. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol. 2015 Mar; 67(3):460-7. PMID: 25234359.
      Citations: 63     Fields:    Translation:HumansPHPublic Health
    83. Hamstra DA, De Rover M, De Rijk RH, Van der Does W. Oral contraceptives may alter the detection of emotions in facial expressions. Eur Neuropsychopharmacol. 2014 Nov; 24(11):1855-9. PMID: 25224104.
      Citations: 12     Fields:    Translation:Humans
    84. Chen RC, Hamstra DA, Sandler HM, Zietman AL. Complications of prostate cancer treatment. Lancet Oncol. 2014 Apr; 15(4):e150. PMID: 24694635.
      Citations: 1     Fields:    Translation:Humans
    85. Hanauer DA, Choi SW, Jong N, Hamstra DA, Li Y, Farley FA, Caird MS, King EA. Osteochondromas after radiation for pediatric malignancies: a role for expanded counseling for skeletal side effects. J Pediatr Orthop. 2014 Apr-May; 34(3):331-5. PMID: 23965908; PMCID: PMC3930617.
      Citations: 3     Fields:    Translation:Humans
    86. Johnson S, Jackson W, Speers C, Feng F, Hamstra D. A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):422-9. PMID: 25407865.
      Citations: 3     Fields:    Translation:Humans
    87. Hamstra DA, Chen RC. RE: Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst. 2014 Mar; 106(3):djt463. PMID: 24586102.
      Citations:    Fields:    Translation:Humans
    88. Shilkrut M, Wu A, Thomas DG, Hamstra DA. Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation. Mol Clin Oncol. 2014 May; 2(3):479-487. PMID: 24772321; PMCID: PMC3999124.
      Citations: 5     
    89. Stenmark MH, Conlon AS, Johnson S, Daignault S, Litzenberg D, Marsh R, Ritter T, Vance S, Kazzi N, Feng FY, Sandler H, Sanda MG, Hamstra DA. Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Radiother Oncol. 2014 Feb; 110(2):291-7. PMID: 24507766.
      Citations: 12     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    90. Hoppe BS, Michalski JM, Mendenhall NP, Morris CG, Henderson RH, Nichols RC, Mendenhall WM, Williams CR, Regan MM, Chipman JJ, Crociani CM, Sandler HM, Sanda MG, Hamstra DA. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer. 2014 Apr 01; 120(7):1076-82. PMID: 24382757; PMCID: PMC4103169.
      Citations: 33     Fields:    Translation:Humans
    91. Hamstra DA. Oncology scan--intermittent androgen deprivation and the randomized evidence. Int J Radiat Oncol Biol Phys. 2013 Nov 01; 87(3):446-8. PMID: 24075270.
      Citations:    Fields:    
    92. Gay HA, Michalski JM, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal C, Litwin M, Kuban D, Hembroff L, Chang P, Sanda MG, PROSTQA Consortium. Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology. 2013 Dec; 82(6):1363-8. PMID: 24139340; PMCID: PMC3904352.
      Citations: 10     Fields:    Translation:Humans
    93. Lao CD, Friedman J, Tsien CI, Normolle DP, Chapman C, Cao Y, Lee O, Schipper M, Van Poznak C, Hamstra D, Lawrence T, Hayman J, Redman BG. Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiat Oncol. 2013 Aug 21; 8:204. PMID: 23965287; PMCID: PMC3765365.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    94. Litzenberg DW, Gallagher I, Masi KJ, Lee C, Prisciandaro JI, Hamstra DA, Ritter T, Lam KL. A measurement technique to determine the calibration accuracy of an electromagnetic tracking system to radiation isocenter. Med Phys. 2013 Aug; 40(8):081711. PMID: 23927308.
      Citations: 2     Fields:    
    95. Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Oct 01; 87(2):275-81. PMID: 23886418.
      Citations: 2     Fields:    Translation:Humans
    96. Jackson WC, Johnson SB, Foster B, Foster C, Li D, Song Y, Vainshtein J, Zhou J, Hamstra DA, Feng FY. Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):99-107. PMID: 24890350.
      Citations: 3     Fields:    Translation:Humans
    97. Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol. 2013 Jul 08; 8:170. PMID: 23835115; PMCID: PMC3718717.
      Citations: 8     Fields:    Translation:Humans
    98. Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer. 2013 Sep 15; 119(18):3287-94. PMID: 23821578.
      Citations: 23     Fields:    Translation:Humans
    99. Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):721-8. PMID: 23664325.
      Citations: 10     Fields:    Translation:Humans
    100. Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, Wei JT, Sanda MG, Michalski JM, PROSTQA Consortium Study Group. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):546-53. PMID: 23561651.
      Citations: 14     Fields:    Translation:Humans
    101. Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng F, Hamstra D. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):554-61. PMID: 23561650.
      Citations: 3     Fields:    Translation:Humans
    102. Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013 May 01; 119(9):1729-35. PMID: 23436283; PMCID: PMC3759976.
      Citations: 37     Fields:    Translation:Humans
    103. Feng FY, Blas K, Olson K, Stenmark M, Sandler H, Hamstra DA. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2013 May 01; 86(1):64-71. PMID: 23462420.
      Citations: 7     Fields:    Translation:Humans
    104. Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, Albrecht-Unger L, Donaghy A, Phelps L, Blas K, Halverson S, Marsh R, Olson K, Feng FY. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1246-53. PMID: 23265567.
      Citations: 19     Fields:    Translation:HumansPHPublic Health
    105. Stenmark MH, Hamstra DA. Re: Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era: A. S. Kibel, J. P. Ciezki, E. A. Klein, C. A. Reddy, J. D. Lubahn, J. Haslag-minoff, J. O. Deasy, J. M. Michalski, D. Kallogjeri, J. F. Piccirillo, D. M. Rabah, C. Yu, M. W. Kattan And A. J. Stephenson; J Urol 2012; 187: 1259-1265. J Urol. 2012 Dec; 188(6):2438-9; author reply 2439-40. PMID: 23088984.
      Citations:    Fields:    Translation:Humans
    106. Shilkrut M, Feng F, Hamstra DA. General commentary to the "management of biochemical recurrence after primary localized therapy for prostate cancer" by darwish o. M. And raj g. V. Front Oncol. 2012; 2:126. PMID: 23061043; PMCID: PMC3459002.
      Citations: 1     
    107. Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer. 2013 Feb 01; 119(3):681-90. PMID: 22893254.
      Citations: 10     Fields:    Translation:Humans
    108. Murgic J, Stenmark MH, Halverson S, Blas K, Feng FY, Hamstra DA. The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer. Radiat Oncol. 2012 Aug 01; 7:127. PMID: 22852797; PMCID: PMC3484035.
      Citations: 2     Fields:    Translation:Humans
    109. Vainshtein J, Abu-Isa E, Olson KB, Ray ME, Sandler HM, Normolle D, Litzenberg DW, Masi K, Pan C, Hamstra DA. Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy. Radiat Oncol. 2012 Jun 09; 7:82. PMID: 22681643; PMCID: PMC3408353.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    110. Amro H, Hamstra DA, Mcshan DL, Sandler H, Vineberg K, Hadley S, Litzenberg D. The dosimetric impact of prostate rotations during electromagnetically guided external-beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):230-6. PMID: 22554583; PMCID: PMC3413775.
      Citations: 13     Fields:    Translation:Humans
    111. Stenmark MH, Vineberg K, Ten Haken RK, Hamstra DA, Feng M. Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancer. Med Dosim. 2012; 37(3):240-4. PMID: 22189029.
      Citations: 2     Fields:    Translation:Humans
    112. Vance SM, Stenmark MH, Blas K, Halverson S, Hamstra DA, Feng FY. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):940-6. PMID: 22056069.
      Citations: 8     Fields:    Translation:Humans
    113. Wu J, Johnson TD, Chenevert TL, Meyer CR, Rehemtulla A, Hamstra DA, Ross BD, Galb?n CJ. Predicting treatment efficacy via quantitative magnetic resonance imaging: a Bayesian joint model. J R Stat Soc Ser C Appl Stat. 2012 01 01; 61(1):83-98. PMID: 22577240; PMCID: PMC3346284.
      Citations:    
    114. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14. PMID: 21934053; PMCID: PMC3831607.
      Citations: 86     Fields:    Translation:HumansPHPublic Health
    115. Kapadia NS, Olson K, Sandler HM, Feng FY, Hamstra DA. Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer. Cancer. 2012 Apr 15; 118(8):2059-68. PMID: 22009287.
      Citations: 6     Fields:    Translation:Humans
    116. Feng FY, Qian Y, Stenmark MH, Halverson S, Blas K, Vance S, Sandler HM, Hamstra DA. Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e361-7. PMID: 21820250.
      Citations: 25     Fields:    Translation:Humans
    117. Litzenberg DW, Balter JM, Hadley SW, Hamstra DA, Willoughby TR, Kupelian PA, Djemil T, Mahadevan A, Jani S, Weinstein G, Solberg T, Enke C, Levine L, Sandler HM. Prostate intrafraction translation margins for real-time monitoring and correction strategies. Prostate Cancer. 2012; 2012:130579. PMID: 22111005; PMCID: PMC3195290.
      Citations: 10     
    118. Halverson S, Schipper M, Blas K, Lee V, Sabolch A, Olson K, Sandler HM, Feng FY, Hamstra DA. The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse. Radiother Oncol. 2011 Dec; 101(3):513-20. PMID: 21703711.
      Citations: 3     Fields:    Translation:Humans
    119. Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e335-44. PMID: 21645976.
      Citations: 9     Fields:    Translation:Humans
    120. Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Sebolt-Leopold JS, Rehemtulla A, Ross BD, Galb?n CJ, Galb?n S. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res. 2011 Jul 15; 17(14):4751-60. PMID: 21527563; PMCID: PMC3139775.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    121. Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM, Hamstra DA. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e351-60. PMID: 21493015.
      Citations: 24     Fields:    Translation:Humans
    122. Oh KS, Hung J, Robertson PL, Garton HJ, Muraszko KM, Sandler HM, Hamstra DA. Outcomes of multidisciplinary management in pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e481-8. PMID: 21470783.
      Citations: 12     Fields:    Translation:Humans
    123. Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1293-301. PMID: 21458924; PMCID: PMC4675045.
      Citations: 15     Fields:    Translation:Humans
    124. Qian Y, Feng FY, Halverson S, Blas K, Sandler HM, Hamstra DA. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):e135-42. PMID: 21345617.
      Citations: 3     Fields:    Translation:Humans
    125. Raldow A, Hamstra DA, Kim SN, Yu JB. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis. Cancer Treat Rev. 2011 Apr; 37(2):89-96. PMID: 20667660.
      Citations: 6     Fields:    Translation:Humans
    126. Hamstra DA, Michalski JM, Roach M, Sandler HM. Do not count out external-beam radiation therapy for high-risk prostate cancer. J Clin Oncol. 2010 Oct 01; 28(28):e518-9; author reply e521-e522. PMID: 20660824.
      Citations:    Fields:    Translation:Humans
    127. Raldow A, Hamstra DA, Kim S, Yu JB. Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy. Oncology (Williston Park). 2010 Jul; 24(8):692-700, 702. PMID: 20718248.
      Citations: 2     Fields:    Translation:Humans
    128. Hamstra DA, Eisbruch A, Naidu MU, Ramana GV, Sunkara P, Campbell KC, Ross BD, Rehemtulla A. Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer. Clin Cancer Res. 2010 May 01; 16(9):2666-76. PMID: 20388849.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    129. Tsien C, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD, Galb?n CJ. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010 May 01; 28(13):2293-9. PMID: 20368564; PMCID: PMC2860441.
      Citations: 84     Fields:    Translation:Humans
    130. Mukherji SK, Chenevert TL, Meyer CR, Hamstra DA, Bland PH, Johnson TD, Moffat BA, Rehemtulla A, Eisbruch A, Ross BD, Galb?n CJ. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol. 2009 08 18; 2(3):184-90. PMID: 19701503; PMCID: PMC2730136.
      Citations: 56     
    131. Wittmann D, Montie JE, Hamstra DA, Sandler H, Wood DP. Counseling patients about sexual health when considering post-prostatectomy radiation treatment. Int J Impot Res. 2009 Sep-Oct; 21(5):275-84. PMID: 19609297; PMCID: PMC2834328.
      Citations:    
    132. Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Ross DJ, Rehemtulla A, Ross BD, Galb?n CJ. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med. 2009 May; 15(5):572-6. PMID: 19377487; PMCID: PMC3307223.
      Citations: 97     Fields:    Translation:Humans
    133. Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, Hamstra DA. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res. 2009 Jan 15; 15(2):589-96. PMID: 19147764.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    134. Hamstra DA, Lee KC, Moffat BA, Chenevert TL, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol. 2008 Dec; 1(4):187-94. PMID: 19043529; PMCID: PMC2582167.
      Citations: 20     
    135. Spalding AC, Hamstra DA. Radiation therapy reduces local failure and improves overall survival in sPNET. Pediatr Blood Cancer. 2008 Jul; 51(1):148; author reply 149-50. PMID: 18273871.
      Citations:    Fields:    Translation:Humans
    136. Hamstra DA, Meyer CR, Johnson TD, Sundgren PC, Tsien C, Lawrence TS, Junck L, Ross DJ, Rehemtulla A, Ross BD, Chenevert TL, Galb?n CJ. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008 Jul 10; 26(20):3387-94. PMID: 18541899; PMCID: PMC3266717.
      Citations: 133     Fields:    Translation:Humans
    137. Vuyyuri SB, Hamstra DA, Khanna D, Hamilton CA, Markwart SM, Campbell KC, Sunkara P, Ross BD, Rehemtulla A. Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis. Clin Cancer Res. 2008 Apr 01; 14(7):2161-70. PMID: 18381958.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    138. Murphy JD, Lucas DR, Somnay YR, Hamstra DA, Ray ME. Gemcitabine-mediated radiosensitization of human soft tissue sarcoma. Transl Oncol. 2008 Mar; 1(1):50-6. PMID: 18607508; PMCID: PMC2510764.
      Citations: 9     
    139. Contessa JN, Hamstra DA. Revoking the privilege: targeting HER2 in the central nervous system. Mol Pharmacol. 2008 Feb; 73(2):271-3. PMID: 17981994.
      Citations: 9     Fields:    Translation:HumansAnimals
    140. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007 Sep 10; 25(26):4104-9. PMID: 17827460.
      Citations: 120     Fields:    Translation:HumansAnimals
    141. Hamstra DA. Primary radiotherapy for childhood ependymoma? Lancet Oncol. 2007 Sep; 8(9):758-9; author reply 760-1. PMID: 17765188.
      Citations: 1     Fields:    Translation:Humans
    142. Lee KC, Hamstra DA, Bhojani MS, Khan AP, Ross BD, Rehemtulla A. Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res. 2007 Mar 15; 13(6):1839-46. PMID: 17363540.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    143. Cao Y, Nagesh V, Hamstra D, Tsien CI, Ross BD, Chenevert TL, Junck L, Lawrence TS. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res. 2006 Sep 01; 66(17):8912-7. PMID: 16951209.
      Citations: 33     Fields:    Translation:Humans
    144. Hamstra DA, Bhojani MS, Griffin LB, Laxman B, Ross BD, Rehemtulla A. Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res. 2006 Aug 01; 66(15):7482-9. PMID: 16885345.
      Citations: 39     Fields:    Translation:AnimalsCells
    145. Bhojani MS, Hamstra DA, Chang DC, Coppola JM, Khan AP, Reddy GR, Ross BD, Rehemtulla A. Imaging of proteolytic activity using a conditional cell surface receptor. Mol Imaging. 2006 Apr-Jun; 5(2):129-37. PMID: 16954027.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    146. Moffat BA, Chen M, Kariaapper MS, Hamstra DA, Hall DE, Stojanovska J, Johnson TD, Blaivas M, Kumar M, Chenevert TL, Rehemtulla A, Ross BD. Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res. 2006 Mar 01; 12(5):1525-32. PMID: 16533777.
      Citations: 15     Fields:    Translation:AnimalsCells
    147. Lee KC, Hamstra DA, Bullarayasamudram S, Bhojani MS, Moffat BA, Dornfeld KJ, Ross BD, Rehemtulla A. Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther. 2006 Jan; 13(2):127-37. PMID: 16163381.
      Citations:    
    148. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji SK, Quint DJ, Gebarski SS, Fan X, Tsien CI, Lawrence TS, Junck L, Rehemtulla A, Ross BD. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A. 2005 Nov 15; 102(46):16759-64. PMID: 16267128; PMCID: PMC1276616.
      Citations: 127     Fields:    Translation:Humans
    149. Hamstra DA, Moffat BA, Hall DE, Young JM, Desmond TJ, Carter J, Pietronigro D, Frey KA, Rehemtulla A, Ross BD. Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study. J Neurooncol. 2005 Jul; 73(3):225-38. PMID: 15980973.
      Citations: 8     Fields:    Translation:HumansAnimals
    150. Hall DE, Moffat BA, Stojanovska J, Johnson TD, Li Z, Hamstra DA, Rehemtulla A, Chenevert TL, Carter J, Pietronigro D, Ross BD. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res. 2004 Dec 01; 10(23):7852-9. PMID: 15585617.
      Citations: 36     Fields:    Translation:AnimalsCells
    151. Hamstra DA, Lee KC, Tychewicz JM, Schepkin VD, Moffat BA, Chen M, Dornfeld KJ, Lawrence TS, Chenevert TL, Ross BD, Gelovani JT, Rehemtulla A. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther. 2004 Nov; 10(5):916-28. PMID: 15509509.
      Citations: 29     Fields:    Translation:Animals
    152. Rehemtulla A, Hamstra DA, Kievit E, Davis MA, Ng EY, Dornfeld K, Lawrence TS. Extracellular expression of cytosine deaminase results in increased 5-FU production for enhanced enzyme/prodrug therapy. Anticancer Res. 2004 May-Jun; 24(3a):1393-9. PMID: 15274300.
      Citations: 4     Fields:    Translation:AnimalsCells
    153. Laxman B, Hall DE, Bhojani MS, Hamstra DA, Chenevert TL, Ross BD, Rehemtulla A. Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A. 2002 Dec 24; 99(26):16551-5. PMID: 12475931; PMCID: PMC139181.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    154. Stegman LD, Rehemtulla A, Hamstra DA, Rice DJ, Jonas SJ, Stout KL, Chenevert TL, Ross BD. Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther. 2000 Jun; 7(12):1005-10. PMID: 10871748.
      Citations: 29     Fields:    Translation:AnimalsCells
    155. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A. 2000 Feb 15; 97(4):1754-9. PMID: 10677530; PMCID: PMC26508.
      Citations: 138     Fields:    Translation:HumansAnimalsCells
    156. Hamstra DA, Pag? M, Maybaum J, Rehemtulla A. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs. Cancer Res. 2000 Feb 01; 60(3):657-65. PMID: 10676650.
      Citations: 5     Fields:    Translation:HumansCells
    157. Hamstra DA, Rice DJ, Pu A, Oyedijo D, Ross BD, Rehemtulla A. Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model. Radiat Res. 1999 Nov; 152(5):499-507. PMID: 10521927.
      Citations: 4     Fields:    Translation:AnimalsCells
    158. Hamstra DA, Rice DJ, Fahmy S, Ross BD, Rehemtulla A. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther. 1999 Aug 10; 10(12):1993-2003. PMID: 10466633.
      Citations: 13     Fields:    Translation:AnimalsCells
    159. Raghunath M, Putnam EA, Ritty T, Hamstra D, Park ES, Tsch?drich-Rotter M, Peters R, Rehemtulla A, Milewicz DM. Carboxy-terminal conversion of profibrillin to fibrillin at a basic site by PACE/furin-like activity required for incorporation in the matrix. J Cell Sci. 1999 Apr; 112 ( Pt 7):1093-100. PMID: 10198291.
      Citations: 30     Fields:    Translation:AnimalsCells
    160. Hamstra DA, Rehemtulla A. Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum Gene Ther. 1999 Jan 20; 10(2):235-48. PMID: 10022548.
      Citations: 8     Fields:    Translation:AnimalsCells
    161. Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 1998 Mar 01; 101(5):1102-10. PMID: 9486981; PMCID: PMC508662.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    162. Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, Iannettoni MD, Orringer MB, Beer DG. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 1997 Dec 15; 57(24):5571-8. PMID: 9407969.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    HAMSTRA's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (500)
    Explore
    _
    Co-Authors (10)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _